Market Size of Photopheresis Products Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR (2024 - 2029) | 5.70 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Photopheresis Products Market Analysis
The Photopheresis Products Market is expected to register a CAGR of 5.70% during the forecast period.
The demand for photopheresis treatments is rising globally, driven by a rise in organ transplantations, cutaneous T-cell lymphoma cases, and favorable reimbursement policies.
Such a huge number of organ transplants globally and in developed regions, such as the United States, is anticipated to increase the adoption of photopheresis products in organ transplantations, driving market growth. For instance, according to the US Department of Health & Human Services data published in March 2024, 46 thousand organ transplants were performed in the United States, and 103,223 people were waiting for an organ transplant in 2023. Thus, the increasing prevalence of organ transplants globally directly correlates with the rising demand for photopheresis due to its pivotal role in managing transplant rejection and related complications, thereby boosting market growth.
The increasing geriatric population worldwide is a major driver for the photopheresis products market, as these treatments are often used for age-related autoimmune and organ transplant conditions. For instance, according to the Australian Institutes of Health and Welfare, in March 2024, the rate of burden from rheumatoid arthritis was 1.6 times as high for females compared with males in 2023 (5.3 and 3.3 DALY per 1,000 population, respectively). Thus, the high burden of autoimmune diseases is expected to increase demand for photopheresis as it can suppress this harmful immune response, which is expected to boost market growth over the forecast period.
Additional factors such as the rising healthcare infrastructure, technological advancement, and growing geriatric population are further expected to drive the market for photopheresis products during the forecast period. The key market players' ongoing initiatives in photopheresis, such as the approvals and launch of innovative products, are anticipated to drive the market studied due to increased adoption.
For instance, in August 2022, Ikaria Australia Pty Ltd, a Mallinckrodt Pharmaceuticals company, launched the THERAKOS CELLEX Photopheresis System in the Australian market. The CELLEX instrument performs the extraction, treatment, and reinfusion of white blood cells for an integrated, closed photopheresis procedure. Similarly, in September 2022, a new apheresis unit was opened in the United Arab Emirates in the Sheikh Shakhbout Medical City (SSMC) as a collaboration between Abu Dhabi Health Services Company (SEHA) and Mayo Clinic. Sheikh Shakhbout Medical City widens the treatment scope for diseases, including rare lymphoma of the skin.
Therefore, factors such as rising organ transplantations, rising prevalence of autoimmune diseases, and rising initiatives from key market players are anticipated to drive market growth. However, the low adoption of photopheresis in pediatric patients and a lack of skilled professionals are expected to hamper market growth.
Photopheresis Products Industry Segmentation
As per the scope of the report, photopheresis (also known as extracorporeal photopheresis [ECP]) is a medical treatment that removes blood through a machine and isolates white blood cells. These isolated white cells are exposed to a medication called 8-methoxy psoralen followed by UVA irradiation before returning the blood to the patient. Photopheresis is used to treat medical conditions such as lung transplant rejection, heart transplant rejection, chronic graft versus host disease (GVHD), and cutaneous T-cell lymphoma (CTCL).
The photopheresis products market is segmented by product type, application, end user, and geography. By product type, the market is segmented into open and closed systems. By application, the market is segmented as graft versus host disease, cutaneous T-cell lymphoma, transplant rejections, and autoimmune diseases. By end user, the market is segmented into hospitals, ambulatory centers, and other end users. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America.
The report offers the value (USD) for the above segments.
| By Product Type | |
| Open System | |
| Closed System |
| By Application | |
| Graft versus Host Disease | |
| Cutaneous T-Cell Lymphoma | |
| Transplant Rejections | |
| Autoimmune Diseases |
| By End User | |
| Hospitals | |
| Ambulatory Centers | |
| Other End Users |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Photopheresis Products Market Size Summary
The photopheresis products market is poised for growth, driven by increasing demand due to the rising prevalence of autoimmune diseases and the growing number of organ transplantations worldwide. The market experienced a temporary decline during the COVID-19 pandemic, as non-elective procedures were postponed and photopheresis was deemed high-risk for certain conditions. However, the market has rebounded post-pandemic, reaching pre-pandemic levels as travel restrictions eased and organ transplantations and cancer treatments resumed. Key factors contributing to market expansion include advancements in healthcare infrastructure, technological innovations, and a growing geriatric population. The approval and launch of innovative products by major market players further bolster market growth, with initiatives such as Japan's approval of the CELLEX system for treating chronic graft versus host disease (cGvHD) exemplifying the ongoing advancements in the field.
In North America, the market is driven by a strong healthcare infrastructure, increased organ donations, and proactive initiatives by key market players. The region's dominance is supported by the presence of blood processing centers and advanced apheresis technologies. The market is characterized by consolidation, with major players engaging in collaborations and acquisitions to strengthen their global positions. The introduction of new apheresis units and products, such as the THERAKOS CELLEX Photopheresis System in Australia, highlights the ongoing efforts to expand the treatment scope for conditions like skin lymphoma. Despite challenges such as low adoption in pediatric patients and a shortage of skilled professionals, the market is expected to continue its growth trajectory, supported by government initiatives and the proven effectiveness of photopheresis in treating conditions like cGvHD.
Photopheresis Products Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rise in Prevalence of Autoimmune Diseases
-
1.2.2 Increasing Technological Advancements
-
-
1.3 Market Restraints
-
1.3.1 Low Adoption of Photopheresis in Pediatric Patients and Lack of Skilled Professionals
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Product Type
-
2.1.1 Open System
-
2.1.2 Closed System
-
-
2.2 By Application
-
2.2.1 Graft versus Host Disease
-
2.2.2 Cutaneous T-Cell Lymphoma
-
2.2.3 Transplant Rejections
-
2.2.4 Autoimmune Diseases
-
-
2.3 By End User
-
2.3.1 Hospitals
-
2.3.2 Ambulatory Centers
-
2.3.3 Other End Users
-
-
2.4 By Geography
-
2.4.1 North America
-
2.4.1.1 United States
-
2.4.1.2 Canada
-
2.4.1.3 Mexico
-
-
2.4.2 Europe
-
2.4.2.1 Germany
-
2.4.2.2 United Kingdom
-
2.4.2.3 France
-
2.4.2.4 Italy
-
2.4.2.5 Spain
-
2.4.2.6 Rest of Europe
-
-
2.4.3 Asia-Pacific
-
2.4.3.1 China
-
2.4.3.2 Japan
-
2.4.3.3 India
-
2.4.3.4 Australia
-
2.4.3.5 South Korea
-
2.4.3.6 Rest of Asia-Pacific
-
-
2.4.4 Middle East and Africa
-
2.4.4.1 GCC
-
2.4.4.2 South Africa
-
2.4.4.3 Rest of Middle East and Africa
-
-
2.4.5 South America
-
2.4.5.1 Brazil
-
2.4.5.2 Argentina
-
2.4.5.3 Rest of South America
-
-
-
Photopheresis Products Market Size FAQs
What is the current Photopheresis Products Market size?
The Photopheresis Products Market is projected to register a CAGR of 5.70% during the forecast period (2024-2029)
Who are the key players in Photopheresis Products Market?
Fresenius Kabi AG, Macopharma, Mallinckrodt Pharmaceuticals, PIT Medical Systems and Haemonetics Corporation are the major companies operating in the Photopheresis Products Market.
